Trial Profile
Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriasis; Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms DANPAPP
- 20 Jan 2021 This trial has been Discontinued in Denmark (Global End Date: 05 Dec 2020), according to European Clinical Trials Database record.
- 02 Jan 2018 New trial record